prazosin has been researched along with Syndrome in 16 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 9.22 | A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016) |
| "To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome." | 9.11 | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004) |
| "We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome." | 9.10 | Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 5.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| "To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 5.22 | A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016) |
| "To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome." | 5.11 | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004) |
| "We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome." | 5.10 | Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003) |
| "To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery." | 4.87 | Risk factors for intraoperative floppy iris syndrome: a meta-analysis. ( Chatziralli, IP; Sergentanis, TN, 2011) |
| " During 12 weeks of prednisone treatment in a dosage of 40 mg daily, her condition markedly deteriorated clinically and hemodynamically as manifested by pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), cardiac output (CO), mixed venous O2 saturation, and systemic vascular resistance (SVR)." | 1.28 | Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. ( Dresner-Feigin, R; Galun, E; Glikson, M; Pollack, A; Rubinow, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Pierce, H | 1 |
| Fainberg, J | 1 |
| Gaffney, C | 1 |
| Aboukhashaba, A | 1 |
| Khan, A | 1 |
| Kashanian, J | 1 |
| Zhang, XY | 1 |
| Luo, SB | 1 |
| Zhang, JY | 1 |
| Meng, ZC | 1 |
| Wang, J | 1 |
| Yan, D | 1 |
| Liang, K | 1 |
| Xu, Z | 1 |
| Zhang, Y | 1 |
| Shamie, N | 1 |
| Daneshmand, S | 1 |
| Mamalis, N | 1 |
| Prata, TS | 1 |
| Palmiero, PM | 1 |
| Angelilli, A | 1 |
| Sbeity, Z | 1 |
| De Moraes, CG | 1 |
| Liebmann, JM | 1 |
| Ritch, R | 1 |
| Chatziralli, IP | 1 |
| Sergentanis, TN | 1 |
| Casuccio, A | 1 |
| Cillino, G | 1 |
| Pavone, C | 1 |
| Spitale, E | 1 |
| Cillino, S | 1 |
| Cheah, PY | 2 |
| Liong, ML | 2 |
| Yuen, KH | 2 |
| Teh, CL | 2 |
| Khor, T | 2 |
| Yang, JR | 2 |
| Yap, HW | 2 |
| Krieger, JN | 2 |
| Minervini, A | 1 |
| Lapini, A | 1 |
| Serni, S | 1 |
| Carini, M | 1 |
| Schwinn, DA | 1 |
| Afshari, NA | 1 |
| Paick, JS | 1 |
| Lee, SC | 1 |
| Ku, JH | 1 |
| Seppi, K | 1 |
| Puschban, Z | 1 |
| Stefanova, N | 1 |
| Scherfler, C | 1 |
| Mueller, J | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Glikson, M | 1 |
| Pollack, A | 1 |
| Dresner-Feigin, R | 1 |
| Galun, E | 1 |
| Rubinow, A | 1 |
| Galassi, AR | 1 |
| Kaski, JC | 1 |
| Pupita, G | 1 |
| Vejar, M | 1 |
| Crea, F | 1 |
| Maseri, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prazosin and Syndrome
| Article | Year |
|---|---|
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; In | 2011 |
5 trials available for prazosin and Syndrome
| Article | Year |
|---|---|
[Triple acupuncture at the Qugu acupoint as an adjunctive therapy for type-Ⅲ chronic prostatitis: Analysis of short- and long-term clinical effects].
Topics: Acupuncture Points; Acupuncture Therapy; Anti-Bacterial Agents; Chronic Disease; Chronic Pain; Combi | 2017 |
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Huma | 2016 |
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; Prazos | 2003 |
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans | 2004 |
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study.
Topics: Adrenergic alpha-Antagonists; Adult; Combined Modality Therapy; Humans; Magnetics; Male; Middle Aged | 2006 |
10 other studies available for prazosin and Syndrome
| Article | Year |
|---|---|
Postorgasmic illness syndrome: potential new treatment options for a rare disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Humans; Male; Orgasm; Prazosin; Quinazolines; Sexual | 2020 |
Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Competence; Fellowships and Scholarships; Female; | 2016 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi | 2008 |
Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Sectional Studies | 2009 |
Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cohort Studies; Doxazosin; Drug Combinations; Humans; | 2011 |
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Chronic Disease; Humans; Male; Pelvic Pain; Prazosin; Prostatitis; Syndrome; Time Factors | 2005 |
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Do | 2005 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, | 2001 |
Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome.
Topics: Adult; Drug Therapy, Combination; Esophageal Motility Disorders; Hemodynamics; Humans; Hypertension, | 1990 |
Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X.
Topics: Adult; Angina Pectoris; Clonidine; Coronary Angiography; Coronary Disease; Electrocardiography; Exer | 1989 |